to X. everyone morning. you Starting thank and Laure, joining with this Slide you, Thank us
including you During on inside. results through third company's some I to walk your will given I with a before opportunities update, thoughts some then will up business days and we comments today's the and call, open XX will return provide the financial closing Q&A. Mark Bradley outlook, and then quarter it performance my
provides X. business and Slide third quarter our operating recent performance highlights.
prior quarter EBITDA attributable of million were XXXX across of million results adjusted Compared repricing. revenue decreased the of pressures loan were to from segment. to part segments term offset as Third just partially primarily year, which Branded generic quarter third our revenues and of total weeks from the X our and $XXX competitive sterile estimates solid X%, ago, preannounced revenues Pharmaceuticals issued our $XXX by
key had is losing impact of stabilize. Varenicline sequential improvement compared to to the competitive exclusivity This including prior and of begun VASOSTRICT as in quarters performance products,
Importantly, year to EBITDA revenue and expectations we as to transition track are on as XXXX deliver growth. our well full
XIAFLEX indications. strong Our the growth anchored both performance on-market was and revenue third XX% of by with performances in total quarter across
first week the We October. during capabilities, of ready-to-use our also injectable launching sterile ADRENALIN including advanced bags
grew In strength the the X%. saw Adjusted addition, business. we EBITDA of cash generation
thank Our the I of repricing confidence. net X.Xx their from leverage was X.Xx continued $X.X billion and term like last loan reduced we successfully our would quarter, to to for completed credit which holders our
strong the volume million average demand increased X% Branded XIAFLEX approximately net XIAFLEX underlying quarter were quarter, to the and driven selling net in XX% revenues. was third X% of versus increase driven performance, into price, revenues approximately increased price grew of an selling about This compared compared and the by increase X average driving Segment Slide year. the by prior increased by This level increase XX% Pharmaceuticals represents segment, to company revenues which $XXX strong segment was Moving performance, to and XXXX. prior to primarily X% year.
physician strong HCP a reflects experience. including branded quarter, grew our demand on previous products the well the Dupuytren's across increasing disease continued XX% focus The in as to $XX relative quarter, Peyronie's grew was segment, as to and remainder patient performance XIAFLEX the improving indications. revenues the both which improved X% During contracture awareness and minus million prior generated established This of compared year. revenues the the the very year. X%
of change XXXX year-over-year competitive Injectable primarily million products. revenues attributable several was prior to as related $XX Sterile temporary quarter revenues $XX supply pressure to this Third below were in of disruptions as well year the million, VASOSTRICT
of the we as year as lap from Importantly, see loss from resolution substantial we exclusivity. expect erosion disruptions by the moderation as impact overall in competition the VASOSTRICT well of the supply to end of the
Turning to Slide X.
Lidoderm, partially Third to decrease year, quarter from to capsules. generic excluding Varenicline segment year. segment for were of revenues drove $XXX Generic grew decrease margin prior primarily by XX% prior due competition and million, of offset points tablets to basis the the was was the Pharmaceutical benefit XXXX Importantly, a this and release patch, of dexlansoprazole, revenue relative lidocaine version XXX X% dexlansoprazole, compared improvements upside It gross delayed and approximately Varenicline
Third International the were which year. quarter XXXX was million, from to essentially the prior Pharmaceuticals unchanged segment $XX revenues compared
future some within growth levers I'd our of business highlight forward, utilizing pillars. performance the Looking Sterile Branded like and to is the
for contraction. XX. rates in treatment increase with the rates impact prefer option Slide a and for nonsurgical have significant a patients patients can diagnosis FDA-approved can therapeutic only options. Both XIAFLEX and those diagnosis to and small Turning who disease low have Peyronie's is nonsurgical Dupuytren's
direct-to-consumer potential of to and inquire a branded seek diagnosis investment our in both patients about options. focused awareness treatment nonsurgical campaigns, We motivating on are combination unbranded and increasing a
indications, business our our increases and Dupuytren's and adoption ago, his sharing locators telling experience. a story. for Increasing Football the to by a local patient patient plan across trained to tailored XIAFLEX new Dupuytren's increase visits years including education we the Pro increase to physician adoption. helped be pleased specialist continue Five practitioners. activation both Hall contracture of critical care access awareness by We Elway, John and to treatment coming patient health where disease-related our XIAFLEX patient weeks, overall In in is websites contracture both campaign, of that a PR Famer and the knowledge launch of to
help believe We acquisition and Annual Accordingly, a high-touch seamless education we interact provider simultaneously. technique reality unveiled Surgery physician option. on by American for objects focused of allowing provides digital the will specialists that refine use the and XXX specialists. the over immersive to physical Hand, as The XIAFLEX XIAFLEX and approach an mixed injection at preferential simulate experience of increase hand our physician hand experience, nonsurgical Meeting their a the treatment learning loyalty to last with them Society month, simulator support a of
help build Sexual patients. their also technology believe to of Annual At and we is to We confidence. recent presentations It HCPs and America training disease injection better XIAFLEX. will this the there continue support important on inject information Peyronie's and real-world advance Medicine their related that support provide Meeting, studies X Society were
XX. to Slide Turning
provided clinical our neurological In for growth XIAFLEX early indications, morning, the we Plantar Phase addition growth Fasciitis update study. and by from XIAFLEX potential new to have on-market musculoskeletal potential the into an This been to expanding we indications. II exploring drive
was on numerical While study numeric compared X.X not showed significant. milligrams scale baseline participants from of The receiving pain statistically improvement to rating the intensity treatment difference XIAFLEX one placebo.
results moderate of analysis However, were clinically an hoc indicates with patients a severe baseline. pain the meaningful that initial for subpopulation to post at
or will indications more a our Alongside determine in opportunities subspecialty specifically ortho in the further work and high-growth garner is tower the to moderate within to presence contracture, which utility Orthopedics and Plantar orthopedic do to with platform, synergistic patient so of data population medicine if our to evaluate category, warranted. a the We to now in force. incremental Dupuytren's sales sports clinical expand detail severe this is
musculoskeletal shot capitated was logical, other cycle indications with semi-attractive provide risk for Our long and life upside very opportunities. a neurological durability. on biologic substantial has R&D goal and clinical that a This with
for entire we well I a Plantar As both at as look allocation program noted, inorganic best use and assess next the business. of opportunities this future indications and Fasciitis full also XIAFLEX the to look our opportunity for as steps at capital for take range fresh will organic the
pillar are critical growth. Injectable to care Turning future Slide second acute capabilities XX. and Sterile our of the
XX are hopeful to pipeline weeks. past Recently, and we customers. introduction pipeline and The last unique receive that evolved manufacturing have very exciting the And establishment opportunity. final more I've years, something needs a we the our we is evolving it capabilities this over my of in is to several report support of and sterile the segment FDA received projects the the by Over for year-end. site, been expanded products indoor the view, inspection into and over that digging of several meet in approval long-term our potential
front an surgical our moment U.S. take our use that our in along to the a opportunity success. acute care segment, and outline XX% product, Greater to future than in wanted The I So sterile factor manufacturing commercial thoughts. footprint, with hospital a Endo hospital brief several is offering centers. foundation to business meaning ERs and of to pipeline of Currently, unique leverage injectables within capabilities provide our a ORs, critical is and hospitals
in greater has best further expanding an protocols. setting ever-growing Hospitals care While patient the acute This quality and ultimately operating translates is world, subject of the hospitals Sterile play. hospital volumes U.S. outcome within is into the reimbursement, the business and these arguably demand. procedure-based procedure the to into costs comes manage which DRG the treatment environment up Injectable capitated patient Is under rates. to both it under to where our This operate means
to product deal and provide constraint, forms With environment, to our error reduce ER, are staff the FDA-approved the pharmacy been nursing hospital finished you've to to the measured complexity tech, offering syringes, and simplicity which is ever such step only an a costs pre-dose use, this Not accurately also a medications final has great as you function rates, medications prefilled importantly, that of but a subject if most and manufactured facilities. in hospital as labor reduce does waste. potential provision to well in know time and as FDA-approved in of improvement bags ready
bags are this launched for demand injectable their an to of waste the creates patient in opportunity ready-to-use ready-to-use planned our faster, sterile formulations with profitability We XX% less better that with Approximately for need. under early meet and This are more vials recently achieve outcomes dosing, ADRENALIN codes. early reimbursement hospital patient along October, pleased the projects with hence, and accurate help product. we our higher pipeline multi-dose to for and
time Our FDA-approved bag and is improved the manufacturer a ID workflow epinephrine and allows treatment for to efficiencies. by and first only bag prepared
plan pipeline. launch development We products and more expect end and before to Sterile XXXX continue two of Injectable our injectable sterile the to progressing
XX. Slide to Moving
overhangs. legacy financial healthy restructuring balance this the was and earlier free that Following a completed has now sheet of Endo is year,
has spendings, funded emergence lower quarter. company is of decreasing from the last prior X.Xx, repricing term X.Xx quickly lower the debt Net significantly the Specifically, loan improvement even the approximately a of a with just at end and significant last week. to impact leverage reduction including now and from
operate having now In creation, matters. addition, its both its alleviated the with other litigation, company significantly on overhangs freedom and legacy has improved and focus to tax
me through call With the turn the rest who of that, us the take Mark, will Mark? let to discussion. financial
